ALZN
Alzamend Neuro, Inc.
Key Financials
Operating Income
$-4496824
↑ 54.7%
Total Assets
$4.6M
↑ 628.8%
EPS (Diluted)
$-11.32
↑ 23.0%
Shareholders' Equity
$4.0M
↑ 253.0%
Net Income
$-4514853
↑ 54.6%
Total Liabilities
$634761.00
↓ 80.3%
Cash & Equivalents
$3.9M
↑ 950.0%
Operating Cash Flow
$-6568186.00
↑ 20.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/17/2026 | View on SEC |
| 4 | 4/16/2026 | View on SEC |
| 8-K | 3/20/2026 | View on SEC |
| 10-Q | 3/11/2026 | View on SEC |
| 424B5 | 3/6/2026 | View on SEC |
| 8-K | 3/6/2026 | View on SEC |
| DEFA14A | 2/26/2026 | View on SEC |
| DEF 14A | 2/26/2026 | View on SEC |
| PRE 14A | 2/9/2026 | View on SEC |
| 4 | 12/30/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALZN |
| Company Name | Alzamend Neuro, Inc. |
| CIK | 1677077 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0430 |
| State of Incorporation | DE |
| Phone | 844-722-6333 |